Kronisk lymfatisk leukæmi

Caspar da Cunha-Bang; Christian Brieghel; Carsten Utoft Niemann

Kronisk lymfatisk leukæmi

Caspar da Cunha-Bang, Christian Brieghel, Carsten Utoft Niemann

Afdeling for Blodsygdomme

Abstract

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the world with approximately 450 new cases yearly in Denmark. The disease is highly heterogeneous, and half of the patients will never require treatment. The standard treatment is chemoimmunotherapy, but highly effective targeted therapies are approved for patients with high-risk disease or relapse as summarised in this review. The Danish CLL guidelines are continuously updated based on results from ongoing clinical trials and international guidelines.

Bidragets oversatte titel	Chronic lymphocytic leukaemia
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	183
Udgave nummer	42
Sider (fra-til)	V03210259
ISSN	0041-5782
Status	Udgivet - 18 okt. 2021

Emneord

Humans
Immunotherapy
Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
Neoplasm Recurrence, Local

Adgang til dokumentet

https://ugeskriftet.dk/videnskab/kronisk-lymfatisk-leukaemi

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{50a8afbefa3e4e83bf37722264bfb5a3,

title = "Kronisk lymfatisk leuk{\ae}mi",

abstract = "Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the world with approximately 450 new cases yearly in Denmark. The disease is highly heterogeneous, and half of the patients will never require treatment. The standard treatment is chemoimmunotherapy, but highly effective targeted therapies are approved for patients with high-risk disease or relapse as summarised in this review. The Danish CLL guidelines are continuously updated based on results from ongoing clinical trials and international guidelines.",

keywords = "Humans, Immunotherapy, Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis, Neoplasm Recurrence, Local",

author = "{da Cunha-Bang}, Caspar and Christian Brieghel and Niemann, {Carsten Utoft}",

year = "2021",

month = oct,

day = "18",

language = "Dansk",

volume = "183",

pages = "V03210259",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "42",

}

TY - JOUR

T1 - Kronisk lymfatisk leukæmi

AU - da Cunha-Bang, Caspar

AU - Brieghel, Christian

AU - Niemann, Carsten Utoft

PY - 2021/10/18

Y1 - 2021/10/18

N2 - Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the world with approximately 450 new cases yearly in Denmark. The disease is highly heterogeneous, and half of the patients will never require treatment. The standard treatment is chemoimmunotherapy, but highly effective targeted therapies are approved for patients with high-risk disease or relapse as summarised in this review. The Danish CLL guidelines are continuously updated based on results from ongoing clinical trials and international guidelines.

AB - Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the world with approximately 450 new cases yearly in Denmark. The disease is highly heterogeneous, and half of the patients will never require treatment. The standard treatment is chemoimmunotherapy, but highly effective targeted therapies are approved for patients with high-risk disease or relapse as summarised in this review. The Danish CLL guidelines are continuously updated based on results from ongoing clinical trials and international guidelines.

KW - Humans

KW - Immunotherapy

KW - Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis

KW - Neoplasm Recurrence, Local

UR - http://www.scopus.com/inward/record.url?scp=85121158533&partnerID=8YFLogxK

M3 - Review

C2 - 34709154

SN - 0041-5782

VL - 183

SP - V03210259

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 42

ER -

Kronisk lymfatisk leukæmi

Abstract

Emneord

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater